Drugs / STIMULAN VG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06283979 | Jun 2025 → Dec 2026 expected | decubitus ulcer, osteomyelitis | Biocomposites Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05539963 | Jan 2023 → Jun 2025 overdue | bone disorder | Biocomposites Ltd | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06808568 Background | — | bone disorder, decubitus ulcer | Biocomposites Ltd | Available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STIMULAN VG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06283979 ↗ |
| Route | Other | “via implantation during debridement surgery on Day 1.” NCT05539963 ↗ |